Ahealth's latest financial statements

Financial performance

• Total revenue: reached RM2.482bil, up 5.5% year over year. Despite a slowdown in market demand, it has continued to grow compared to the same period last year.

• Operating profit: reached RM26.9 mil, up 6.8% year over year.

• Profit before and after tax: Profit before tax was RM26.3 mil, YoY decreased by 11.4%; profit after tax was RM2.12 mil, YoY decreased by 12.7%. The decline was mainly due to reduced earnings of the associated company Straits Apex Group Sdn Bhd.

Investment and strategic trends

• Property purchase: The Group purchased industrial properties in Malacca at a total price of MYR 66.5 million, with plans to expand production capacity.

• Funding: Part of the purchase will be raised through a MYR 50 million loan from HSBC Malaysia Ltd.

• Singapore subsidiary expansion: Apex Pharma Marketing Pte Ltd leases additional warehouse space to support operational efficiency and new business growth.

Market and operational challenges

• Changes in market demand: Although the first quarter of 2023 brought record high revenue due to high incidence of respiratory diseases (Covid drugs), market demand showed signs of slowing in the first quarter of 2024.

• Affiliated company losses: The negative exercise at Straits Apex Group and Next Ortho Investment Holdings Pte Ltd affected overall profits.

outlooks